Abiopharma

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Integer to Present at 2025 Wells Fargo Healthcare Conference on Sept. 4

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Core Molding Technologies to Present and Host 1x1 Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 26, 2025

New Form 10-Q - Mereo BioPharma Group plc Filed: 2025-08-12 AccNo: 0001193125-25-178489 Size: 9 MB

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

New Form 8-K - LIFECORE BIOMEDICAL, INC. \DE\ Filed: 2025-08-12 AccNo: 0001005286-25-000115 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form SCHEDULE 13D/A - REGIONAL HEALTH PROPERTIES, INC Filed: 2025-08-12 AccNo: 0001193805-25-001177 Size: 9 KB

Mereo BioPharma Reports Second Quarter 2025 Financial Results

Intensity Therapeutics, Inc. Regains Compliance with Nasdaqs Minimum Stockholders Equity Requirement

New Form 8-K - ADC Therapeutics SA Filed: 2025-08-12 AccNo: 0001771910-25-000006 Size: 387 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Mereo BioPharma Group plc Filed: 2025-08-12 AccNo: 0000950170-25-106924 Size: 508 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

"Prime Time," a Branded Peyronies Disease Commercial forXIAFLEX® (collagenase clostridium histolyticum)

New Form 10-Q - Grace Therapeutics, Inc. Filed: 2025-08-12 AccNo: 0001140361-25-030398 Size: 5 MB